GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zentalis Pharmaceuticals Inc (NAS:ZNTL) » Definitions » EV-to-FCF

Zentalis Pharmaceuticals (Zentalis Pharmaceuticals) EV-to-FCF : -2.07 (As of May. 09, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Zentalis Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Zentalis Pharmaceuticals's Enterprise Value is $436.33 Mil. Zentalis Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-210.55 Mil. Therefore, Zentalis Pharmaceuticals's EV-to-FCF for today is -2.07.

The historical rank and industry rank for Zentalis Pharmaceuticals's EV-to-FCF or its related term are showing as below:

ZNTL' s EV-to-FCF Range Over the Past 10 Years
Min: -2.98   Med: -2.17   Max: -1.62
Current: -2.07

During the past 6 years, the highest EV-to-FCF of Zentalis Pharmaceuticals was -1.62. The lowest was -2.98. And the median was -2.17.

ZNTL's EV-to-FCF is ranked worse than
100% of 381 companies
in the Biotechnology industry
Industry Median: 6.23 vs ZNTL: -2.07

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-09), Zentalis Pharmaceuticals's stock price is $12.52. Zentalis Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.330. Therefore, Zentalis Pharmaceuticals's PE Ratio for today is At Loss.


Zentalis Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Zentalis Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zentalis Pharmaceuticals EV-to-FCF Chart

Zentalis Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - -20.78 -22.04 -4.82 -3.03

Zentalis Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.09 -7.39 -4.62 -3.03 -3.20

Competitive Comparison of Zentalis Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Zentalis Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zentalis Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zentalis Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Zentalis Pharmaceuticals's EV-to-FCF falls into.



Zentalis Pharmaceuticals EV-to-FCF Calculation

Zentalis Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=436.326/-210.553
=-2.07

Zentalis Pharmaceuticals's current Enterprise Value is $436.33 Mil.
Zentalis Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-210.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zentalis Pharmaceuticals  (NAS:ZNTL) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Zentalis Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=12.52/-3.330
=At Loss

Zentalis Pharmaceuticals's share price for today is $12.52.
Zentalis Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.330.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Zentalis Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Zentalis Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Zentalis Pharmaceuticals (Zentalis Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1359 Broadway, Suite 1710, New York, NY, USA, 10018
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
Executives
Kimberly Blackwell director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
David Michael Johnson director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Carrie Brownstein officer: Chief Medical Officer 500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701
Kevin D. Bunker officer: Chief Operating Officer C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Melissa B, Epperly officer: Chief Financial Officer C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Jan Skvarka director C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Cam Gallagher director 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Diana Hausman director C/O ONCOTHYREON INC., 2601 FOURTH AVE, SUITE 500, SEATTLE WA 98121
Iris Roth officer: Chief Operating Officer C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Andrea Paul officer: General Counsel 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Anthony Y Sun director, officer: President & CEO C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10106
Alexis Pinto officer: Chief Legal Officer C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Dimitris Voliotis officer: SVP, Clinical Development C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Enoch Kariuki director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901

Zentalis Pharmaceuticals (Zentalis Pharmaceuticals) Headlines

From GuruFocus